Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718776 | 1.00 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL22601413 | 1.00 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL22601414 | 0.85 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL24500360 | 0.83 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10183384 | 0.79 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10740595 | 0.75 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL867517 | 0.73 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10183389 | 0.71 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL29444520 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24146781 | 0.69 | PARP1 (0.44) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | PI4KA 98/4885PI4K2B 138/4885PI4K2A 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.